FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

The Food and Drug Administration’s agenda for developing a policy on cannabidiol use in dietary supplements and other non-drug products includes two reports due to Congress within six months. After those action items, however, the list is bare.

The FDA has little in the way of good information, particularly about safety in hemp-derived CBD’s use in myriad products already available to consumers without a requirement for pre-market approval by the agency, it can